25 search results for: itch

Contribution of Type 2 Cytokines to Inflammation and <b>Itch</b> in AD, PN, and CSU

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

Under the <b>Itch</b>y Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

5 min

Dermatology

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

2 min

Dermatology

Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min

Dermatology

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

36 min

Type 2 Inflammation

Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type 2 inflammation contributes to key symptoms of inflammatory diseases across organs

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

Infographic

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

5 min

Dermatology

An infographic describing the etiology, epidemiology, challenges in diagnosis and patient burden of CPUO.

expert video

Type 2 Inflammation Within Skin Tissue in AD

4 min

Dermatology

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region